Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jacob P. Thyssen"'
Autor:
Jacob P. Thyssen, Thomas Bieber, C. Elise Kleyn, Audrey Nosbaum, Susanne Grond, Helmut Petto, Elisabeth Riedl, Andreas Wollenberg
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor approved for moderate-to-severe atopic dermatitis (AD) in adults. Objectives To evaluate absolute Eczema Area and Severity Index (EASI) and SCORing of Atopic Dermatitis (SCORAD) o
Externí odkaz:
https://doaj.org/article/5099d3aa9d4a4a06bf314cc7ba25d33b
Autor:
Jacob P. Thyssen, Thomas Werfel, Sebastien Barbarot, Hamish J.A Hunter, Evangeline Pierce, Luna Sun, Lisa Cirri, Andrew S. Buchanan, Na Lu, Andreas Wollenberg
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Patients who completed the originating studies, BREEZE-AD1 (NCT03334396), BREEZE-AD2(NCT03334422), and BREEZE-AD7 (NCT03733301), were eligible for enrollment in the multicenter,phase-3, long-term extension study BREEZE-AD3 (NCT03334435). M
Externí odkaz:
https://doaj.org/article/c4c894e54c7248608b959261c2cae564
Autor:
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, is approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We report integrated baricitinib safety data in patients with up to 3.9-years exposur
Externí odkaz:
https://doaj.org/article/ca9ed6e40be942ef9798f73046c71ec1
Autor:
Steven R. Feldman, Jacob P. Thyssen, Marco Boeri, Robert Gerber, Maureen P. Neary, Amy Cha, Brett Hauber, Joseph C. Cappelleri, Jason Xenakis, Colton Leach, Joshua Zeichner
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose: Topical treatments for mild-to-moderate (MM) atopic dermatitis (AD) include emollients, corticosteroids, calcineurin inhibitors, a Janus kinase inhibitor, and a phosphodiesterase 4 inhibitor, which differ in multiple ways. This study
Externí odkaz:
https://doaj.org/article/381c24a10916409ba5aff352aa5817bc
Autor:
Hans Christian Ring, Claus Zachariae, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 8, Pp 3205-3207 (2022)
Papulopustular rosacea is notoriously a challenge to treat, and treatment options are scarce. Only limited data exist on the use of azithromycin in treatment of papulopustular rosacea. However, the unique pharmacokinetics of azithromycin may have sev
Externí odkaz:
https://doaj.org/article/8bef2c60c1a84714a48a0bbc4ed3d77f
Publikováno v:
Journal of Dermatological Treatment, Vol 29, Iss 1, Pp 100-101 (2018)
Novel and innovative treatment options for atopic dermatitis (AD) are underway. The recent advancements in understanding AD are reminiscent of the progress made in psoriasis research over a decade ago.
Externí odkaz:
https://doaj.org/article/bade8c3b90fe4423a16df6567303c9bd
Autor:
Gitte Færk, Elisabeth Søndergaard, Lone Skov, Jacob Pontoppidan Thyssen, Kirsten Skamstrup Hansen, Susanne Reventlow
Publikováno v:
Scandinavian Journal of Primary Health Care, Pp 1-10 (2024)
Objective To explore how the parents of children with atopic dermatitis and allergic diseases such as food allergy, allergic rhinoconjunctivitis, and asthma experience interactions with the Danish healthcare system over time.Design and methods A qual
Externí odkaz:
https://doaj.org/article/a306ac7dfb754927b4e3a64c7b26081b